Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies
The DOI matches its Crossref record; 83 of the 84 references it cites were found in a registry or an index.
Abstract
The long serum t1/2 of IgGs is ensured by their interaction with the neonatal Fc receptor (FcRn), which salvages IgG from intracellular degradation. Fc glycosylation is thought not to influence FcRn binding and IgG longevity in vivo. In this article, we demonstrate that hypersialylation of asparagine 297 (N297) enhances IgG serum persistence. This polarized glycosylation is achieved using a novel Fc mutation, a glutamate residue deletion at position 294 (Del) that endows IgGs with an up to 9-fold increase in serum lifespan. The strongest impact was observed when the Del was combined with Fc mutations improving FcRn binding (Del-FcRn+). Enzymatic desialylation of a Del-FcRn+ mutant or its production in a cell line unable to hypersialylate reduced the in vivo serum t1/2 of the desialylated mutants to that of native FcRn+ mutants. Consequently, our study proves that sialylation of the N297 sugar moiety has a direct impact on human IgG serum persistence.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is beneficial as more sialylated glycoforms have been shown to have a longer in vivo half‐life. 38 , 39”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [39]
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229 · cited 4×
“This medicinal prospect became reality with the advent of immortalization of Ab-producing clonal B cells following their somatic cell fusion with myeloma cells (2).”
BackgroundMethodInfluentialFcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Carbohydrate-Specific Receptors of the Liver
Ashwell, G., & Harford, J. (1982) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.51.070182.002531 · Cited by 1,914 · cited 2×
“acid on galactose residues masks the epitope, thereby inhibiting their removal from circulation (62).”
BackgroundCartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835 · cited 1×
“ably because the IgG low-fucose content already resulted in high binding to this receptor, reducing the additional impact of the mutations (15).”
BackgroundAnti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Self-citationPaul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457 · cited 1×
“Two assays were set up to characterize the interaction of the IgG variants with hFcRn: 1) biolayer interferometry (BLI) and 2) competitive binding assay on FcRn-expressing Jurkat cells (1).”
MethodThe Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins
Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M., & Dwek, R. A. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141702 · Cited by 1,307
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · cited 1×
“To eliminate sialylated residues from glycans, the IgG variant T5A-74Del was treated with sialidase A (GK80040; Prozyme) to release a(2,3)-, a(2,6)-, a(2,8)-, and a(2,9)-linked N-acetylneuraminic acid.”
MethodShields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
The role of sialic acid in determining the survival of glycoproteins in the circulation
Morell, A. G., Gregoriadis, G., Scheinberg, I. H., Hickman, J., & Ashwell, G. (1971) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)76994-4 · Cited by 1,072 · cited 1×
“(non-IgG) from their degradation in the liver (61).”
BackgroundMusolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · cited 1×
“To eliminate sialylated residues from glycans, the IgG variant T5A-74Del was treated with sialidase A (GK80040; Prozyme) to release a(2,3)-, a(2,6)-, a(2,8)-, and a(2,9)-linked N-acetylneuraminic acid.”
MethodStrategies and challenges for the next generation of therapeutic antibodies
Beck, A., Wurch, T., Bailly, C., & Corvaia, N. (2010) · Nature Reviews Immunology · doi:10.1038/nri2747 · Cited by 847 · cited 1×
“85%), which are classical modifications described for mAbs (51).”
BackgroundIntravenous immunoglobulin therapy: how does IgG modulate the immune system?
Schwab, I., & Nimmerjahn, F. (2013) · Nature Reviews Immunology · doi:10.1038/nri3401 · Cited by 820
Engineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803
Ferrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A. C., Stihle, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108455108 · Cited by 770 · cited 1×
“action by steric hindrance within the Fc cavity, obstructing the carbohydrate–carbohydrate interaction (17).”
BackgroundThe 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex
Sondermann, P., Huber, R., Oosthuizen, V., & Jacob, U. (2000) · Nature · doi:10.1038/35018508 · Cited by 719
Krapp, S., Mimura, Y., Jefferis, R., Huber, R., & Sondermann, P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01250-0 · Cited by 674 · cited 1×
“magnetic resonance (69) and crystallographic (66) analyses showed that these residues, in particular F241 and F243, are in close contact with the N-glycan chains (68).”
BackgroundEnhanced antibody half-life improves in vivo activity
Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I. W. L., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1601 · Cited by 653
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
Dall'Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 646
A Functional Role for Antibodies in Tuberculosis
Lu, L. L., Chung, A. W., Rosebrock, T. R., Ghebremichael, M., Yu, W. H., Grace, P. S., Schoen, M. K., Tafesse, F., Martin, C., Leung, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.072 · Cited by 571 · cited 1×
“Sialylated Abs are natural constituents of the humoral response that are induced over the course of viral and bacterial infections (80, 81).”
BackgroundTerminal sugars of Fc glycans influence antibody effector functions of IgGs
Raju, T. S. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.007 · Cited by 521 · cited 1×
“dues has little influence on IgG t1/2 (13, 59, 60).”
BackgroundType I and type II Fc receptors regulate innate and adaptive immunity
Pincetic, A., Bournazos, S., DiLillo, D. J., Maamary, J., Wang, T. T., Dahan, R., Fiebiger, B.-M., & Ravetch, J. V. (2014) · Nature Immunology · doi:10.1038/ni.2939 · Cited by 514 · cited 1×
“dows a potent anti-inflammatory capacity in models of inflammatory disease (21, 22, 82).”
BackgroundYoshida, M., Claypool, S. M., Wagner, J. S., Mizoguchi, E., Mizoguchi, A., Roopenian, D. C., Lencer, W. I., & Blumberg, R. S. (2004) · Immunity · doi:10.1016/j.immuni.2004.05.007 · Cited by 471 · cited 1×
“FcRn exerts numerous functions in immunological (27, 28) and nonimmunological (29, 30) mechanisms of catabolism and transport.”
BackgroundGoetze, A. M., Liu, Y. D., Zhang, Z., Shah, B., Lee, E., Bondarenko, P. V., & Flynn, G. C. (2011) · Glycobiology · doi:10.1093/glycob/cwr027 · Cited by 467 · cited 7×
“F(ab9)2-aggregated IgGs were then incubated under gentle agitation for 1 h at 30˚C on the saturated ELISA plates (at the exception of FcgRI-coated plates) at serial dilutions (from 1 mg/ml to 31.25 ng/ml).”
BackgroundInfluentialScallon, B. J., Tam, S. H., McCarthy, S. G., Cai, A. N., & Raju, T. S. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.09.005 · Cited by 396
Crystal Structure at 2.8 Å of an FcRn/Heterodimeric Fc Complex
Martin, W. L., West, A. P., Gan, L., & Bjorkman, P. J. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00230-1 · Cited by 391 · cited 1×
“These variants generally include two to three substitutions in or close to the FcRn binding site localized at the CH2/CH3 interdomain region (34, 35).”
BackgroundIgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity
Wang, T. T., Sewatanon, J., Memoli, M. J., Wrammert, J., Bournazos, S., Bhaumik, S. K., Pinsky, B. A., Chokephaibulkit, K., Onlamoon, N., Pattanapanyasat, K., et al. (2017) · Science · doi:10.1126/science.aai8128 · Cited by 369
Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences
Acqua, W. F. D., Woods, R. M., Ward, E. S., Palaszynski, S. R., Patel, N. K., Brewah, Y. A., Wu, H., Kiener, P. A., & Langermann, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.5171 · Cited by 368
Robbie, G. J., Criste, R., Dall'Acqua, W. F., Jensen, K., Patel, N. K., Losonsky, G. A., & Griffin, M. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01285-13 · Cited by 366
Zhu, X., Meng, G., Dickinson, B. L., Li, X., Mizoguchi, E., Miao, L., Wang, Y., Robert, C., Wu, B., Smith, P. D., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.5.3266 · Cited by 322 · cited 1×
“such as macrophages, monocytes, and dendritic cells (26).”
BackgroundModulating IgG effector function by Fc glycan engineering
Li, T., DiLillo, D. J., Bournazos, S., Giddens, J. P., Ravetch, J. V., & Wang, L.-X. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1702173114 · Cited by 322
A Novel Role for the IgG Fc Glycan: The Anti-inflammatory Activity of Sialylated IgG Fcs
Anthony, R. M., & Ravetch, J. V. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9405-6 · Cited by 318
Petkova, S. B., Akilesh, S., Sproule, T. J., Christianson, G. J., Al Khabbaz, H., Brown, A. C., Presta, L. G., Meng, Y. G., & Roopenian, D. C. (2006) · International Immunology · doi:10.1093/intimm/dxl110 · Cited by 314 · cited 1×
“These hFcRn mice, unlike WT mice, have been shown to be a reliable surrogate for studying human IgG serum t1/2 (36).”
BackgroundStavenhagen, J. B., Gorlatov, S., Tuaillon, N., Rankin, C. T., Li, H., Burke, S., Huang, L., Johnson, S., Bonvini, E., & Koenig, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0696 · Cited by 284
An Engineered Human IgG1 Antibody with Longer Serum Half-Life
Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., & Tsurushita, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.346 · Cited by 282
Structural Comparison of Fucosylated and Nonfucosylated Fc Fragments of Human Immunoglobulin G1
Matsumiya, S., Yamaguchi, Y., Saito, J.-I., Nagano, M., Sasakawa, H., Otaki, S., Satoh, M., Shitara, K., & Kato, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.034 · Cited by 278 · cited 1×
“No notable conformational change is observed for fucosylated Abs (73).”
BackgroundKaplon, H., & Reichert, J. M. (2018) · mAbs · doi:10.1080/19420862.2018.1415671 · Cited by 244 · cited 3×
“To eliminate sialylated residues from glycans, the IgG variant T5A-74Del was treated with sialidase A (GK80040; Prozyme) to release a(2,3)-, a(2,6)-, a(2,8)-, and a(2,9)-linked N-acetylneuraminic acid.”
BackgroundMethodYeung, Y. A., Leabman, M. K., Marvin, J. S., Qiu, J., Adams, C. W., Lien, S., Starovasnik, M. A., & Lowman, H. B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804182 · Cited by 237
Washburn, N., Schwab, I., Ortiz, D., Bhatnagar, N., Lansing, J. C., Medeiros, A., Tyler, S., Mekala, D., Cochran, E., Sarvaiya, H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422481112 · Cited by 225
Lund, J., Takahashi, N., Pound, J. D., Goodall, M., & Jefferis, R. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.11.4963 · Cited by 216
The Structural Role of Antibody N-Glycosylation in Receptor Interactions
Subedi, G. P., & Barb, A. W. (2015) · Structure · doi:10.1016/j.str.2015.06.015 · Cited by 216
Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease
Pagan, J. D., Kitaoka, M., & Anthony, R. M. (2018) · Cell · doi:10.1016/j.cell.2017.11.041 · Cited by 204 · cited 1×
“dows a potent anti-inflammatory capacity in models of inflammatory disease (21, 22, 82).”
BackgroundYu, M., Brown, D., Reed, C., Chung, S., Lutman, J., Stefanich, E., Wong, A., Stephan, J.-P., & Bayer, R. (2012) · mAbs · doi:10.4161/mabs.20737 · Cited by 203
A common glycan structure on immunoglobulin G for enhancement of effector functions
Lin, C.-W., Tsai, M.-H., Li, S.-T., Tsai, T.-I., Chu, K.-C., Liu, Y.-C., Lai, M.-Y., Wu, C.-Y., Tseng, Y.-C., Shivatare, S. S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513456112 · Cited by 200
FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis
Vidarsson, G., Stemerding, A. M., Stapleton, N. M., Spliethoff, S. E., Janssen, H., Rebers, F. E., de Haas, M., & van de Winkel, J. G. (2006) · Blood · doi:10.1182/blood-2006-05-024539 · Cited by 198 · cited 1×
“FcRn exerts numerous functions in immunological (27, 28) and nonimmunological (29, 30) mechanisms of catabolism and transport.”
BackgroundStructural characterization of a human Fc fragment engineered for lack of effector functions
Oganesyan, V., Gao, C., Shirinian, L., Wu, H., & Dall'Acqua, W. F. (2008) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444908007877 · Cited by 197 · cited 1×
“effector functions but had no major impact on Fc glycosylation nor Fc conformation (79).”
BackgroundNMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic
Barb, A. W., & Prestegard, J. H. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.511 · Cited by 186 · cited 1×
“magnetic resonance (69) and crystallographic (66) analyses showed that these residues, in particular F241 and F243, are in close contact with the N-glycan chains (68).”
BackgroundSialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis
Ohmi, Y., Ise, W., Harazono, A., Takakura, D., Fukuyama, H., Baba, Y., Narazaki, M., Shoda, H., Takahashi, N., Ohkawa, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms11205 · Cited by 170 · cited 1×
“dows a potent anti-inflammatory capacity in models of inflammatory disease (21, 22, 82).”
BackgroundPolyak, M. J., & Deans, J. P. (2002) · Blood · doi:10.1182/blood.v99.9.3256 · Cited by 159 · cited 2×
“6E12 (42) in the YB2/0 cell line (EMABling platform, LFB Biomanufacturing).”
BackgroundMethodGillis, C. M., Gouél‐Cheron, A., Jönsson, F., & Bruhns, P. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00254 · Cited by 157 · cited 3×
“To eliminate sialylated residues from glycans, the IgG variant T5A-74Del was treated with sialidase A (GK80040; Prozyme) to release a(2,3)-, a(2,6)-, a(2,8)-, and a(2,9)-linked N-acetylneuraminic acid.”
BackgroundMethodProgress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy
Almagro, J. C., Daniels-Wells, T. R., Perez-Tapia, S. M., & Penichet, M. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01751 · Cited by 157
Efficient mucosal vaccination mediated by the neonatal Fc receptor
Ye, L., Zeng, R., Bai, Y., Roopenian, D. C., & Zhu, X. (2011) · Nature Biotechnology · doi:10.1038/nbt.1742 · Cited by 157 · cited 1×
“FcRn exerts numerous functions in immunological (27, 28) and nonimmunological (29, 30) mechanisms of catabolism and transport.”
BackgroundChapter 4 Multitasking by Exploitation of Intracellular Transport Functions
Ward, E. S., & Ober, R. J. (2009) · Advances in Immunology · doi:10.1016/s0065-2776(09)03004-1 · Cited by 156
Structural Characterization of Anti-Inflammatory Immunoglobulin G Fc Proteins
Ahmed, A. A., Giddens, J., Pincetic, A., Lomino, J. V., Ravetch, J. V., Wang, L.-X., & Bjorkman, P. J. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.07.006 · Cited by 154 · cited 2×
“crystal structure has been elucidated (74).”
BackgroundHigh-resolution carbohydrate profiling by capillary gel electrophoresis
Guttman, A. (1996) · Nature · doi:10.1038/380461a0 · Cited by 148 · cited 1×
“Classically (50), sequential topdown enzymatic digestions with fucosidase, sialidase, and galac-”
Backgroundvan Bueren, J. J. L., Rispens, T., Verploegen, S. A. B. W., van der Palen‐Merkus, T., Stapel, S. O., Workman, L. J., James, H. R., van Berkel, P. H. C., van de Winkel, J. G. J., Platts‐Mills, T. A. E., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1912 · Cited by 136
de Romeuf, C., Dutertre, C., Garff‐Tavernier, M. L., Fournier, N., Gaucher, C., Glacet, A., Jorieux, S., Bihoreau, N., Behrens, C. K., Béliard, R., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06974.x · Cited by 134
Self-citationTeylaert, B., Meurice, E., Bobowski, M., Harduin-Lepers, A., Gaucher, C., Fontayne, A., Jorieux, S., & Delannoy, P. (2011) · BMC Biotechnology · doi:10.1186/1472-6750-11-1 · Cited by 123 · cited 1×
“These cells naturally express low levels of FUT8 fucosyltransferase (45), resulting in low fucosylation of the Fc glycan moiety known to strongly enhance ADCC (46, 47).”
BackgroundSelf-citationChevreux, G., Tilly, N., & Bihoreau, N. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.04.030 · Cited by 112 · cited 1×
“Electronic parameters were optimized with purified Ab as described before (43, 44).”
MethodFiebiger, B. M., Maamary, J., Pincetic, A., & Ravetch, J. V. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505292112 · Cited by 111 · cited 2×
“In addition, the anti-inflammatory effect endowed to naturally sialylated Fc was fully recapitulated by the F241A variant, confirming structural and functional mimicry (78).”
BackgroundBaudino, L., Shinohara, Y., Nimmerjahn, F., Furukawa, J.-I., Nakata, M., Martínez-Soria, E., Petry, F., Ravetch, J. V., Nishimura, S.-I., & Izui, S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6664 · Cited by 107
Extending human IgG half-life using structure-guided design
Booth, B. J., Ramakrishnan, B., Narayan, K., Wollacott, A. M., Babcock, G. J., Shriver, Z., & Viswanathan, K. (2018) · mAbs · doi:10.1080/19420862.2018.1490119 · Cited by 107 · cited 1×
“YTE variant, which increases mAb serum t1/2 in humans at the cost of highly decreasing the thermal stability of the mAb (83).”
BackgroundKao, D., Danzer, H., Collin, M., Groß, A., Eichler, J., Štambuk, J., Lauc, G., Lux, A., & Nimmerjahn, F. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.11.027 · Cited by 93 · cited 1×
“N297 (N297A or N297G), lack effector functions (ADCC and complement-dependent cytotoxicity [CDC]) (14), whereas the absence of fucose residues on the Fc glycan moiety is associated”
BackgroundPulmonary administration of therapeutic proteins using an immunoglobulin transport pathway
Bitonti, A. J., & Dumont, J. A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.015 · Cited by 89 · cited 1×
“FcRn exerts numerous functions in immunological (27, 28) and nonimmunological (29, 30) mechanisms of catabolism and transport.”
BackgroundHumanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies
Proetzel, G., & Roopenian, D. C. (2014) · Methods · doi:10.1016/j.ymeth.2013.07.005 · Cited by 84 · cited 1×
“Studies using marketed mAbs, for which PK data in humans and/or primates were available, convincingly demonstrate that the hFcRn mice reliably predicted their serum t1/2 in humans (54, 55).”
MethodEngineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies
Yu, X., Baruah, K., Harvey, D. J., Vasiljevic, S., Alonzi, D. S., Song, B.-D., Higgins, M. K., Bowden, T. A., Scanlan, C. N., & Crispin, M. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4014375 · Cited by 84 · cited 2×
“mational flexibility of the CH2 domain (57, 70, 74).”
BackgroundSubedi, G. P., Hanson, Q. M., & Barb, A. W. (2014) · Structure · doi:10.1016/j.str.2014.08.002 · Cited by 81 · cited 2×
“This restricted Fc structure resembles an “open” conformation that is favorable to FcgRIIIA binding (70).”
BackgroundPaz-Ares, L. G., Gomez-Roca, C., Delord, J.-P., Cervantes, A., Markman, B., Corral, J., Soria, J.-C., Bergé, Y., Roda, D., Russell-Yarde, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8888 · Cited by 80 · cited 1×
“Fucosylation has been formally excluded to impact serum t1/2 (65).”
BackgroundEngineering host cell lines to reduce terminal sialylation of secreted antibodies
Naso, M. F., Tam, S. H., Scallon, B. J., & Raju, T. S. (2010) · mAbs · doi:10.4161/mabs.2.5.13078 · Cited by 74 · cited 1×
“dues has little influence on IgG t1/2 (13, 59, 60).”
BackgroundCrispin, M., Bowden, T. A., Coles, C. H., Harlos, K., Aricescu, A. R., Harvey, D. J., Stuart, D. I., & Jones, E. Y. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.02.033 · Cited by 72 · cited 1×
“increased FcgRIIIA binding, adopts an asymmetrically open conformation with an expansion of the interdomain space (72), whereas low-fucosylated Fc seems, instead, to accommodate a glycan of FcgRIIIA by a subtle local conformation alteration”
BackgroundTam, S. H., McCarthy, S. G., Brosnan, K., Goldberg, K. M., & Scallon, B. J. (2013) · mAbs · doi:10.4161/mabs.23836 · Cited by 69
Monnet, C., Jorieux, S., Souyris, N., Zaki, O., Jacquet, A., Fournier, N., Crozet, F., de Romeuf, C., Bouayadi, K., Urbain, R., et al. (2014) · mAbs · doi:10.4161/mabs.27854 · Cited by 54 · cited 4×
“As previously described (40), the C6A-74 and T5A-74 variants displayed increased t1/2 (ratio variant/WT = ∼1.”
BackgroundMethodSelf-citationMonnet, C., Jorieux, S., Urbain, R., Fournier, N., Bouayadi, K., de Romeuf, C., Behrens, C. K., Fontayne, A., & Mondon, P. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00039 · Cited by 52 · cited 5×
“Using random mutagenesis and a pH-dependent phage display selection process (40, 41), we previously identified several FcRnoptimized (FcRn) variants, of which, one variant (C6A-66) raised our particular interest.”
BackgroundMethodSelf-citationMulti-Site N-glycan mapping study 1: Capillary electrophoresis – laser induced fluorescence
Szekrényes, Á., Park, S. S., Santos, M., Lew, C., Jones, A. W., Haxo, T., Kimzey, M. J., Pourkaveh, S., Szabó, Z., Sosic, Z., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1107687 · Cited by 44 · cited 8×
“Abbreviations used in this article: ADCC, Ab-dependent cell-mediated cytotoxicity; BLI, biolayer interferometry; CDC, complement-dependent cytotoxicity; CE, capillary electrophoresis; Del, glutamate residue deletion at position 294; DLS, dynamic light scattering; FcRn, neonatal Fc receptor; FcRn+, FcRn-optimized; GlcN…”
MethodInfluentialCapillary electrophoresis in the N-glycosylation analysis of biopharmaceuticals
Guttman, A. (2013) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2013.04.006 · Cited by 35 · cited 8×
“Abbreviations used in this article: ADCC, Ab-dependent cell-mediated cytotoxicity; BLI, biolayer interferometry; CDC, complement-dependent cytotoxicity; CE, capillary electrophoresis; Del, glutamate residue deletion at position 294; DLS, dynamic light scattering; FcRn, neonatal Fc receptor; FcRn+, FcRn-optimized; GlcN…”
MethodInfluentialThe interactions of therapeutic antibodies with Fc receptors
Albanesi, M., & Daëron, M. (2012) · Immunology Letters · doi:10.1016/j.imlet.2012.02.005 · Cited by 35 · cited 1×
“cross-linking of FcgRs widely expressed on many innate immune cells, such as NK cells, monocytes, macrophages, and neutrophils (4).”
BackgroundEnhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines
Mimura, Y., Kelly, R. M., Unwin, L., Albrecht, S., Jefferis, R., Goodall, M., Mizukami, Y., Mimura-Kimura, Y., Matsumoto, T., Ueoka, H., et al. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.11.009 · Cited by 35 · cited 1×
“Likewise, desialylation of the F243A variant had no effect on its ADCC activity (58), and desialylation of the F241A variant had no influence on its anti-inflammatory properties (78), demonstrating”
BackgroundGlyco-Engineering of Human IgG-Fc to Modulate Biologic Activities
Jefferis, R. (2016) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201017666161029225929 · Cited by 35 · cited 4×
“is unexpected because IgG serum t1/2 is dominantly regulated by the FcRn (13).”
BackgroundInfluentialYu, C., Gao, K., Zhu, L., Wang, W., Wang, L., Zhang, F., Liu, C., Li, M., Wormald, M. R., Rudd, P. M., et al. (2016) · Scientific Reports · doi:10.1038/srep20029 · Cited by 25
Henninot, A., Terrier, A., Charton, J., Urbain, R., Fontayne, A., Deprez, B. P., & Beghyn, T. B. (2015) · Analytical Biochemistry · doi:10.1016/j.ab.2015.08.006 · Cited by 17 · cited 1×
“Electronic parameters were optimized with purified Ab as described before (43, 44).”
MethodSelf-citationFournier, N., Jacque, É., Fontayne, A., Derache, D., Dupont, G., Verhaeghe, L., Baptista, L., Dehenne, A., Dezetter, A.-S., Terrier, A., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1451283 · Cited by 10
Self-citation
Cited by
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 316
“The collection of mutations were studied as individual mutations to elucidate the function of the deletion of Glu294 (115).”
BackgroundInfluentialConsiderations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 302
The history of IgG glycosylation and where we are now
Cobb, B. A. (2020) · Glycobiology · doi:10.1093/glycob/cwz065 · Cited by 193
“Indeed, Fc sialylation increases circulatory half-life of antibodies (Bas et al. 2019), likely by avoiding ligation by both the asialoglycoprotein receptor (ASGPR) in the liver and the neonatal Fc receptor FcRn.”
BackgroundThe Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
Gogesch, P., Dudek, S., van Zandbergen, G., Waibler, Z., & Anzaghe, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168947 · Cited by 172
“that hypersialylation of N297 is able to extend the half-life of IgG [170].”
BackgroundImpact of structural modifications of IgG antibodies on effector functions
Damelang, T., Brinkhaus, M., van Osch, T. L. J., Schuurman, J., Labrijn, A. F., Rispens, T., & Vidarsson, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1304365 · Cited by 123
Metadata
- Authors
- Bas, M., Terrier, A., Jacque, E., Dehenne, A., Pochet-Béghin, V., Beghin, C., Dezetter, A.-S., Dupont, G., Engrand, A., Beaufils, B., Mondon, P., Fournier, N., de Romeuf, C., Jorieux, S., Fontayne, A., Mars, L. T., & Monnet, C.
- Affiliations
- Inserm (FR)
- LFB (France) (FR)
- LFB Biotechnologies , 91958 Courtaboeuf Cedex ,
- LFB Biotechnologies , 59011 Lille Cedex ,
- Corresponding author
- Bas, Mathilde
- Dupont, Gilles
- Mondon, Philippe
- Fournier, Nathalie
- Jorieux, Sylvie
- Fontayne, Alexandre
- ORCID
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-03-01
- Volume
- 202
- Issue
- 5
- Pages
- 1582-1594
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2912324466
- Cited by
- 82
- References
- 84
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 11 · 2023: 11 · 2022: 15 · 2021: 13 · 2020: 10 · 2019: 8
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-17-CE15-0028)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- neonatal Fc receptor, Fc glycosylation, FcRn binding, therapeutic antibodies, desialylation, antibody persistence
- MeSH terms
- Animals, Antibodies, Half-Life, Humans, Immunoglobulin G, Immunoglobulin Fc Fragments, Mice, Knockout, Mice, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.